Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
SIRIUS-SLE1
Lupus Phase III
- 7 weeks
- 1st site activated worldwide and second patient enrolled globally
1501-001
Advanced Solid Tumours Phase I
- 7.1 weeks
- 1st site activated worldwide and Canadian FPI
ProHer
Breast Cancer Phase IIIb
- 10.6 weeks
- 1st site activated worldwide
ProHer
Breast Cancer Phase IIIb
- 25 weeks
TCD 17240
Advanced Solid Tumours Phase I/II
- 16.1 weeks
- Canadian regulatory delay 1st site activated worldwide and Canadian FPI
VICTORION-2
Cardiology Phase III
- 7.7 weeks
- 1st site activated worldwide
VICTORION-2
Cardiology Phase III
- 8 weeks
- 2nd site activated worldwide
VICTORION-2
Cardiology Phase III
- 8.7 weeks
- 3rd site activated worldwide and FPI globally
VICTORION-2
Cardiology Phase III
- 9.9 weeks
- 5th site activated worldwide
224035 (NERT)
Solid Tumors Phase I/II
- 10.4 weeks
EFC17905
Hemophilia Phase III
- 10.4 weeks
- 1st site activated in Canada
1245-0256
Nephrology (Chronic kidney disease) Phase III
- 9 weeks
- 1st site activated in Canada
1493-0002
Idiopathic Pulmonary Fibrosis Phase IIa
- 15.6 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 6.4 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 8.2 weeks
20230005
Prostate Cancer Phase III
- 13.4 weeks
- 1st site activated in Canada and Canadian FPI
20230222
Elevated Lipoprotein(a) Phase III
- 3.8 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 8 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 8.4 weeks
20230222
Elevated Lipoprotein(a) Phase III
- 11.4 weeks